Results 151 to 160 of about 241,963 (315)
P50 Gossypiboma causing SLE and dermatomyositis overlap [PDF]
, 2020 Liubov Borukhson +2 more
openalex +1 more source
Arthritis &Rheumatology, Accepted Article.Objective The multinational, phase 3, double‐blind, placebo‐controlled TULIP‐SC trial evaluated the efficacy and safety of subcutaneous anifrolumab in adults who have moderate‐to‐severe SLE activity, despite receiving standard therapy. Methods Adults with SLE received subcutaneous anifrolumab 120 mg or placebo once weekly for 52 weeks (1:1 ...
Susan Manzi +12 more
wiley +1 more source
Lymphocytic interstitial pneumonia as a manifestation of SLE and secondary Sjogren's syndrome [PDF]
, 2013 Daniel Fantozzi Garcia, Lary Young
openalex +1 more source
Arthritis &Rheumatology, Accepted Article.Objective GLP‐1 receptor agonists (GLP‐1RAs) and SGLT2 inhibitors (SGLT2is) facilitate weight loss and exhibit immunomodulatory effects, but their impact on the risk of developing autoimmune rheumatic diseases (ARDs) is unclear. We compared ARD incidence following initiation of GLP‐1RAs, or SGLT2is, vs.
Derin Karacabeyli +4 more
wiley +1 more source
Dysregulation of U12‐Type Splicing in Lupus Neutrophils
Arthritis &Rheumatology, Accepted Article.Abstract. Objective Neutrophil dysfunction is a hallmark of systemic lupus erythematosus (SLE), but its molecular basis remains unclear. This study explores transcriptional and post‐transcriptional changes in low‐density granulocytes (LDGs), a proinflammatory neutrophil subset expanded in SLE, focusing on NADPH oxidase (Nox) function and minor intron ...
Luz P. Blanco +11 more
wiley +1 more source
A Novel Gene CDC27 Causes SLE and Is Associated With the Disease Activity
, 2022 Shunlai Shang +9 more
openalex +1 more source
CO73 Overview of COA Measures in SLE Clinical Trials and Label Claims [PDF]
, 2023 Naomi Suminski, Zorana Zupan, K. Rüdell
openalex +1 more source